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Abstract: This study reports the plasma glutathione concentrations in a double-blind, randomized, controlled, 2 × 2
cross-over study in which healthy participants consumed conventional milk (2 × 250 mL per day) containing both A1
and A2 types of β-casein, or milk containing only A2 type β-casein. Beta-casomorphin-7 (BCM-7), a peptide uniquely
derived from the A1 type of β-casein, was previously reported to downregulate glutathione expression in human gut
epithelial and neuronal cell lines by limiting cysteine uptake. The current human study demonstrates that consumption
of milk containing only A2 β-casein was associated with a greater increase in plasma glutathione concentrations
compared with the consumption of milk containing both β-casein types, and did not increase plasma BCM-7
concentrations compared with the washout diet in the study participants. Thus, milk containing only A2 β-casein and
not A1 β-casein has the potential to promote the production of the antioxidant glutathione in humans.
Clinical Trial Registration: ClinicalTrials.gov; identifier: NCT02406469
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Introduction
Disturbances in glutathione (GSH) and redox homeosta-
sis contribute to the pathophysiological processes l-
eading to neurodegenerative diseases [1], pancreatitis
[2], and diseases associated with abnormal cell differenti-
ation [3]. Therefore, maintaining redox balance is im-
portant in the context of disease prevention. In a recent
study, we showed that exposure to β-casomorphin-7
(BCM-7), a proline-rich opioid peptide derived from
bovine β-casein, caused a decrease of intracellular GSH
concentrations in cultured neuronal SH-SY5Y cells [4].
This reduction in GSH was driven by a reduction in
cellular uptake of cysteine, the rate-limiting precursor
for GSH synthesis. Exposure to BCM-7 also reduced the
ratio of reduced GSH to oxidized GSH (glutathione
disulfide) as a marker of redox status, and the ratio of S-
adenosylmethionine to S-adenosylhomocysteine as a
marker of cellular methylation capacity. These results in-
dicate that BCM-7 is a potential modulator of GSH.
BCM-7 is a bioactive peptide with high affinity to μ-
opioid receptors. It is uniquely produced by proteolysis of
the A1 but not the A2 type of β-casein in cow’s milk by
digestive enzymes [5, 6]. β-casein is present in cow’s milk
at a concentration of approximately 10 mg/mL and exists
as one of a number of variants that are classed as either
A1 or A2 type based on the flanking carboxyl amino acid
residue and subsequently the potential to yield BCM-7.
Either or both of these β-casein types may be expressed in
milk, depending on the cow’s genetic makeup. The differ-
ences in the products generated by the proteolytic digestion
of the A1 and A2 types of β-casein are due to a point
mutation at amino acid residue 67 in the 209-amino acid
β-casein protein. A histidine at this position in the A1 type
readily allows enzymatic hydrolysis, whereas a proline at
this position in the A2 type sterically hinders proteolytic
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cleavage [5]. By contrast, proteolysis of the A2 type of β-
casein yields BCM-9, an opioid peptide with a much lower
affinity for opioid receptors [5] and has demonstrable and
contrasting effects on cell function and growth to BCM-7
[7]. However, Cieslinska et al. reported that BCM-7 was
also generated from homogenous milk containing A2 β-
casein, albeit at a level about four-times lower than its gen-
eration from homogenous milk containing A1 β-casein [8].
Although a previous report from the European Food and
Safety Authority [9] acknowledged the production of
BCM-7 from milk containing A1 β-casein, no physiological
effects were reported. However, emerging preclinical and
clinical evidence indicates that BCM-7 produced from A1
β-casein can have physiological effects e.g. [10–14].
Results of in vitro studies may not be reliably extrapolated
to physiological outcomes in animals and humans. Several
factors might influence the systemic concentrations of
BCM-7 in animal and human studies, including the
amount of BCM-7 produced from A1 β-casein contained
in a typical serving of milk, the half-life of BCM-7 in the
gastrointestinal tract, degradation by brush border dipepti-
dyl peptidase-4 (DPP-4) and the rate of transport of BCM-
7 across the gastrointestinal tract into the systemic or
potentially lymphatic circulation. Furthermore, other milk
metabolites, notably those derived from whey proteins,
have been reported to influence GSH concentrations by
promoting cysteine absorption and providing a substrate
for GSH synthesis [15, 16]. Therefore, it is necessary to
conduct animal and human studies to examine if the effects
of BCM-7 on GSH concentrations observed in vitro are
also apparent in vivo following the consumption of A1 type
protein and potential exposure to BCM-7.
In a preliminary in vivo study using rabbits, it was
observed that consumption of a diet containing the A1
type of β-casein was associated with decreased cysteine
concentrations in the ileum and decreased GSH concen-
trations in the blood, liver, and brain compared with
consumption of the A2 type (Additional file 1: Figure S1).
These data indicate that, if BCM-7 is not absorbed into
the systemic circulation, GSH downregulation may occur
because of limited intestinal cysteine uptake from the
small intestine. Thus, it was speculated that a reduction in
cysteine absorption into the circulation, secondary to
downregulation of cellular cysteine uptake, contributed to
the reduction in systemic GSH concentrations, which was
coupled with reduced GSH concentrations in the brain.
While these in vitro and in vivo results were consistent, it
is necessary to extend this investigation to clinical trials in
order to determine if the observed effects of the A1 and
A2 types of β-casein impart corresponding effects on
circulating GSH concentrations in humans.
In consideration of these earlier observations from in
vitro and in vivo studies, the effects of A1 and A2 types
of β-casein on GSH concentrations were compared by
collecting plasma samples from participants who
consumed milk containing either the mixed A1/A2 type
of β-casein or milk containing only the A2 type of β-
casein in a recent double-blind, randomized, controlled,
2 × 2 cross-over study [12]. The design of the study is
shown in Fig. 1. Plasma BCM-7 was also measured to
determine if the systemic concentrations were differen-
tially affected by the two diets, and if there was a correl-
ation between the BCM-7 and GSH concentrations.
Methods
Study design
The design of the study is described in an earlier
publication describing the effects of A1 and A2 β-casein
consumption on aspects of digestive function, serum
borne immune and inflammatory markers and cognitive
function [12]. Because commercially available milk
usually contains both A1 and A2 β-casein, we used a com-
mercial milk product as the reference product, as well as
milk containing only A2 β-casein, as described previously
Fig. 1 Study design. A1 =milk containing A1 and A2 β-casein; A2 =milk containing only A2 β-casein; GSH = glutathione. Modified from [9]
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[12]. Eligible Chinese males or females included those
aged 25–68 years who irregularly consumed milk, had
self-reported mild to moderate digestive discomfort after
milk consumption, and had normal electrocardiograms
and blood pressure during quiet respiration. A total of 21
males and 24 females with a mean ± standard deviation
age of 46.6 ± 14.0 years were enrolled. Twenty-three had
confirmed lactase deficiency based on the results of urin-
ary galactose tests.
The participants consumed commercially available
conventional milk containing A1 and A2 types of β-
casein (A1/A2) in phase 1 or commercially available
milk containing only the A2 type of β-casein (A2) in
phase 2 (A1/A2➔A2; sequence 1), or vice versa
(A2➔A1/A2; sequence 2). The ratio of A1 to A2 β-casein
in milk containing both types of β-casein was determined
to be 42:58 by ultra-performance liquid chromatography
method with diode array detection and tandem mass
spectrometry. Each study phase lasted 2 weeks with 2-week
washout periods before entering phase 1 and between
phases 1 and 2. The participants were instructed to
consume 250 mL of milk after 2 meals per day, every day.
The subjects were prohibited from consuming other dairy
products, but could consume non-dairy milk products dur-
ing the study. The study was conducted in accordance with
the Declaration of Helsinki as amended in Seoul 2008 and
was approved by the ethics committee of the Shanghai
Nutrition Society (approval number: SNSIRB#2014[002]).
The study was registered with ClinicalTrials.gov (identifier:
NCT02406469). All subjects provided written informed
consent prior to inclusion in the study.
Blood samples were collected at baseline and at the
end of each study phase for the measurement of a range
of biomarkers, including GSH and BCM-7. Plasma was
stored at −80 °C until required for assays. Several other
biomarkers were measured and the results are published
elsewhere [12].
Measurement of total plasma GSH
Plasma samples were thawed in ice, and 5 μL of a 0.4 N
perchloric acid solution was added to 200 μL of plasma to
precipitate any remaining proteins. The total protein con-
centration was calculated and used to normalize GSH con-
centrations as previously described [17]. Total GSH
concentrations were measured using a commercially avail-
able glutathione assay kit (Sigma-Aldrich, St. Louis, MO,
USA). The kit involves catalytic conversion of GSH with
5,5′-dithio-2-nitrobenzoic acid and GSSG is recycled by
glutathione reductase to release NADP+, resulting in the
formation of two 5-thio-2-nitrobenzoic acid molecules that
form a yellow color measured at 412 nm. The results were
calculated based on the nmol of 5-thio-2-nitrobenzoic acid
formed as min−1 mg−1 protein, which was converted to
nmol/mg of protein. The GSH concentration was measured
twice for each sample in independent assays.
Measurement of plasma BCM-7 concentrations
BCM-7 concentrations were measured in blood samples
obtained at 3 h after a meal. Plasma samples were
treated with diprotin-B to inhibit DPP-4 activity. BCM-7
was measured by high performance liquid chromatog-
raphy coupled to mass spectrometry (MS) at an exter-
nal laboratory in the multiple reaction monitoring
(MRM) mode (Pharmaceutical Analysis Center, School
of Pharmacy, Second Military Medical University,
Shanghai). The method used to measure BCM-7 is
described in more detail in the Additional file 1.
Statistical analysis
GSH concentrations were highly skewed based on
the Kolmogorov–Smirnov test. Therefore, the GSH
concentrations were analyzed using the Wilcoxon two-
sample test with phase and cross-over as fixed effects,
and P < 0.05 was taken to indicate a statistically significant
phase or cross-over effect. Although BCM-7 concentra-
tions were not skewed based on the Kolmogorov–Smirnov
test, similar analyses were also performed for the BCM-7
concentrations.
Results
The median GSH concentrations measured at the start
and end of each study phase in both sequences are
depicted in Fig. 2. Results of the Wilcoxon two-sample
test are shown in Additional file 1: Table S1. Consump-
tion of milk containing only the A2 β-casein type was
associated with significantly greater increases in plasma
GSH concentrations from baseline to the end of the
study phase compared with the consumption of milk
containing both β-casein types. This increase occurred
in both sequences irrespective of which milk product
was consumed first. The mean ± standard error of the
mean change in GSH concentrations from baseline was
4.01 ± 0.61 nmol/mL for milk containing A2 β-casein
compared with 1.99 ± 0.50 nmol/mL for milk containing
both types of β-casein. The change in GSH concentra-
tions from baseline with the A2 type of β-casein tended
to be greater in phase 1 (Sequence A2➔A1/A2) than in
phase 2 (Sequence A1/A2➔A2) (4.07 vs. 2.70 nmol/mL).
Plasma BCM-7 concentrations were significantly greater
in samples obtained during consumption of milk contain-
ing both β-casein types than at baseline during consump-
tion of milk containing A2 β-casein (Additional file 1: Table
S2). The BCM-7 concentrations were not significantly dif-
ferent between samples obtained after consumption of milk
containing A2 β-casein and the washout/baseline phases.
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Discussion
The objective of the current analyses was to elucidate
the effects of consuming milk containing the A1 or A2
types of β-casein on circulating GSH concentrations in
humans, using blood samples obtained in a randomized
2 × 2 cross-over study [13]. The present results indicate
that the consumption of milk containing only A2 β-casein
was associated with greater increases in plasma GSH
concentrations compared with the consumption of milk
containing both β-casein types, and this was independent
of a cross-over effect. The potential physiological benefits
of elevated GSH concentrations are due to an elevated
plasma antioxidant capacity, which allows aerobic metab-
olism to proceed without incurring damage from accumu-
lating reactive oxygen species (ROS), while maintaining
the homeostatic redox equilibrium [18]. Because GSH also
plays a major role in detoxification, the two-fold higher
plasma GSH concentration associated with the consump-
tion of milk containing only A2 β-casein may provide
greater protection against a range of environmental
exposures. Reduced GSH concentrations are implicated in
a range of diseases, including neurodegenerative, cardio-
vascular, pulmonary, immune, and inflammatory diseases,
as well as cystic fibrosis. Hence, elevated GSH concentra-
tions could be beneficial to patients with such diseases;
however, any direct beneficial correlation between milk
containing A2 β-casein and such diseases needs to be
clinically investigated.
Although we did not measure cysteine concentrations
in the current study, prior studies showed that whey
protein, which does not yield BCM-7 during proteolysis,
promotes cysteine absorption and the synthesis of GSH
[15, 19–21]. By contrast, the opioid peptides derived from
β-casein and wheat gluten protein inhibit cysteine uptake,
decrease GSH concentrations and the anti-oxidant poten-
tial (i.e., decrease the GSH/glutathione disulfide ratio)
[17], with subsequent epigenetic consequences [17, 22].
Although epigenetic changes were not assessed in the
current study, such changes could contribute to the
underlying elevated GSH concentrations in the second
phase of the current study, especially because such epi-
genetic changes are sustained for a long time [17, 22].
Hence, the potential epigenetic effects of these opioid
peptides warrant further clinical investigation.
The results obtained in this randomized cross-over
study are consistent with the results of these prior
studies. Eliminating the A1 type of β-casein from the
milk diet allowed for greater increases in GSH synthesis,
likely through eliminating the inhibitory effects of BCM-
7 on cysteine uptake by the small intestine, as demon-
strated in animal studies and in cells exposed to BCM-7
[17]. This is also supported by the lower BCM-7 concen-
trations observed in the A2 β-casein periods compared
with the A1/A2 β-casein periods in the present study.
It is also notable that, even though BCM-7 concentra-
tions were proportionately greater after consumption of
milk containing both β-casein types than after consumption
of milk containing the A2 type (Additional file 1: Table S2),
the concentrations were lower than those reported to elicit
biological effects in cultured human gut epithelial or neur-
onal cells [17]. Additionally, the concentrations were lower
than those in individuals with neurological disorders or
DPP-4 deficiency [23]. This observation is indicative that
the measurements of plasma BCM-7 may be misleading,
Fig. 2 Median glutathione (GSH) concentrations before and after consumption of milk. Participants consumed milk containing both the A1
and A2 types, or only the A2 type of β-casein. Data are shown for the first of two repeated measures in each participant; the results of both
measures were similar. The phase difference was statistically significant (P = 0.0059) but the cross-over difference was not significant (P = 0.7615)
(Wilcoxon two-sample test). A1 =milk containing A1 and A2 β-casein; A2 =milk containing only A2 β-casein; BL = baseline; WO=washout
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because BCM-7 transport and subsequent systemic tissue
exposure might be influenced by alternative transport
mechanisms. Thus, the chaotrophic environment of peptide
extraction procedures seemingly rules out sequestering or
compartmentalizing of BCM-7 by blood borne molecules
or cells, and opens up the possibility of endocytosis or
binding of macrophages and subsequent uptake by
dendritic cells through the lymphatic system. This mechan-
ism was proposed by Martin et al. to explain the transport
of macromolecules from the small intestine to other tissues
in the body [24], and the observation implies that BCM-7
concentrations should be measured in other tissue compo-
nents, such as lymph tissue, in future studies.
Another notable finding is that BCM-7 was detected
in baseline samples, which were obtained after a dairy
washout phase. These findings indicate that A1 β-casein
protein was not entirely eliminated from the diet, prob-
ably because dairy protein is present in non-milk foods,
including processed foods, allowing the production of
BCM-7 from dairy proteins or caseinates. Changes in
the expression of DPP-4 could also influence the
systemic BCM-7 concentrations.
These observations and prior findings support the
proposition that BCM-7 may act by inhibiting cysteine
absorption via gut epithelial cells, ultimately reducing
the circulating GSH concentrations. Other dietary and
physiological factors are also expected to influence the
circulating GSH concentrations, and may explain the
differences in GSH concentrations between the A2 β-
casein phases. Although it was not possible to examine
the direct impact of complete elimination of dietary
BCM-7 on circulating GSH concentrations, the diet-
dependent changes observed in the present study
indicate that the residual BCM-7 concentrations de-
tected in the A2 β-casein phase participants were
comparable to the washout period without supplemen-
tary A1 β-casein consumption and did not adversely
affect GSH uptake.
In conclusion, the results of this study suggest that
daily consumption of commercially available conven-
tional milk is associated with an increase in GSH
concentrations, possibly as a consequence of increased
supply of cysteine in whey protein. However, the magni-
tude of this increase in GSH concentrations was greater
when the participants consumed milk containing the
A2 type of β-casein as compared with milk containing
both A1 and A2 β-casein. This elevation might be
attenuated by the presence of the A1 type of β-casein
relative to milk containing only the A2 type of β-
casein. These results suggest that eliminating the A1
type of β-casein from milk may allow for a greater in-
crease in GSH concentrations or maximize the poten-
tial for GSH production, and hence confer greater
antioxidant capacity.
Additional file
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